Key facts
- It has raised $20K; the latest was Accelerator/Incubator ($20K) in May 2025.
- Notable investors include Fraunhofer Venture, HGS START accelerator, Arise, Germany's Federal Ministry of Economics and Technology, Institute for Biomedical Translation.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for InhalPlus
- ·The full record, as it builds
Funding rounds
No funding rounds for InhalPlus are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InhalPlus
Developer of innovative inhalation technologies designed for non-invasive drug delivery to premature infants, newborns, and adults. The Company's platform offers preventative, effective, and safe inhaled therapy, enabling patients to improve their lives sustainably.
- Sector
- Healthcare
- HQ
- Hanover, Germany
- Founded
- 2023
- Employees
- 4
- Website
- inhalplus.com/
- Ownership
- Privately Held (backing)
InhalPlus doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InhalPlus shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InhalPlus in its N-PORT filings yet. We sweep new filings monthly.